Decision Impact

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER1) node-negative breast cancer.
J. Albanell, A. Gonzalez, M. Ruiz-Borrego, et al.
Ann Oncol.:

Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer.
Partin JF, Mamounas EP.
Annals of Surgical Oncology:

The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.
Geffen DB, Abu-Ghanem S, Sion-Vardy N, Braunstein R, Tokar M, Ariad S, Delgado B, Bayme M, Koretz M.
Ann Oncol.:

Physician Survey of the Effect of the 21-Gene Recurrence Score Assay Results on Treatment Recommendations for Patients With Lymph Node–Positive, Estrogen Receptor–Positive Breast Cancer
Ruth Oratz, MD, FACP, Benjamin Kim, MD, MPhil, Calvin Chao, MD, Stanley Skrzypczak, MS, Caron Ory, RN, MSN, Roberto Bugarini, DStat, and Michael Broder, MD, FACOG
Journal of Oncology Practice 2011.

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection.
Shelly S. Lo,*Patricia B. Mumby, ­John Norton, ­Karen Rychlik, ­Jeffrey Smerage, ­Joseph Kash, ­Helen K. Chew, ­Ellen R. Gaynor, ­Daniel F. Hayes, ­Andrew Epstein, ­and Kathy S. Albain

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20.
Eleftherios P. Mamounas,*­Gong Tang, ­Bernard Fisher, ­Soonmyung Paik, ­Steven Shak, ­Joseph P. Costantino, ­Drew Watson, ­Charles E. Geyer Jr, ­D. Lawrence Wickerham, ­and Norman Wolmark

The influence of a gene expression profile on breast cancer decisions.
Henry L, Stojadinovic A, Swain SM et al.
Journal of Surgical Oncology:319–323.

Does Oncotype DX recurrence score affect management of patients with early –stage breast cancer?
Asad J, Jacobson A, Estabrook A et al.
Am J Manag Care. 2008; American Journal of Surgery:527–529.


Low Recurrence Score by the Oncotype DX Breast Cancer Assay Rarely Results in Recommendation for or Administration of Chemotherapy: A Pooled Analysis
P Hall, S Skrzypczak, G Palmer
Abstract #2601: Poster Session

Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer
R Oratz, D Paul, AL Cohn, SM Sedlacek
3(4):182-186.

Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen
S Paik
12(6):631-635.


A Retrospective Analysis of the Impact of Oncotype DX Low Recurrence Score Results on Treatment Decisions in a Single Academic Breast Cancer Center
H Liang, AM Brufsky, BB Lembersky, P Rastogi, VG Vogel
Abstract #2061 : Poster Session


Evaluation of Practice Patterns in the Treatment of Node-Negative, Hormone-Receptor Positive Breast Cancer Patients with the Use of the Oncotype DX Assay at the University of Pennsylvania
C Erb, KR Fox, M Patel, K Hook, A DeMichele, C Kaplan, S Domchek
Abstract #3082 : Poster Session


Prospective Multi-Center Study of the Impact of the 21-Gene Recurrence Score (RS) Assay on Medical Oncologist (MO) and Patient (PT) Adjuvant Breast Cancer (BC) Treatment Selection
SS Lo, J Norton, PB Mumby, J Smerage, J Kash, HK Chew, D Hayes, A Epstein, KS Albain
Abstract #577 : Poster Session

Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers
R Simon
23(29):7332-7341.


Impact of Oncotype DX™ on Decision Making in Breast Cancer Clinical Practice
R Oratz, D Paul, A Cohn, S Sedlacek
Abstract #2049 : Poster Session


Prospective Multi-Center Study of the Impact of the 21-Gene Recurrence Score Assay on Patient Satisfaction, Anxiety and Decisional Conflict for Adjuvant Breast Cancer Treatment Selection
PB Mumby, SS Lo, J Norton, J Smerage, K Joseph, HK Chew, D Hayes, KS Albain
Abstract #1092 : Poster Session